Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.
COVID-19
Cardiovascular disease
Diabetes
Hypertension
Mortality
SARS-CoV-2
Severity
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
07
2020
accepted:
21
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
The aim of this study is to evaluate the impact of diabetes, hypertension, cardiovascular disease and the use of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) with severity (invasive mechanical ventilation or intensive care unit admission or O2 saturation < 90%) and mortality of COVID-19 cases. Systematic review of the PubMed, Cochrane Library and SciELO databases was performed to identify relevant articles published from December 2019 to 6th May 2020. Forty articles were included involving 18.012 COVID-19 patients. The random-effect meta-analysis showed that diabetes mellitus and hypertension were moderately associated respectively with severity and mortality for COVID-19: Diabetes [OR 2.35 95% CI 1.80-3.06 and OR 2.50 95% CI 1.74-3.59] Hypertension: [OR 2.98 95% CI 2.37-3.75 and OR 2.88 (2.22-3.74)]. Cardiovascular disease was strongly associated with both severity and mortality, respectively [OR 4.02 (2.76-5.86) and OR 6.34 (3.71-10.84)]. On the contrary, the use of ACEI/ARB, was not associate with severity of COVID-19. In conclusion, diabetes, hypertension and especially cardiovascular disease, are important risk factors for severity and mortality in COVID-19 infected people and are targets that must be intensively addressed in the management of this infection.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to evaluate the impact of diabetes, hypertension, cardiovascular disease and the use of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) with severity (invasive mechanical ventilation or intensive care unit admission or O2 saturation < 90%) and mortality of COVID-19 cases.
METHODS
METHODS
Systematic review of the PubMed, Cochrane Library and SciELO databases was performed to identify relevant articles published from December 2019 to 6th May 2020. Forty articles were included involving 18.012 COVID-19 patients.
RESULTS
RESULTS
The random-effect meta-analysis showed that diabetes mellitus and hypertension were moderately associated respectively with severity and mortality for COVID-19: Diabetes [OR 2.35 95% CI 1.80-3.06 and OR 2.50 95% CI 1.74-3.59] Hypertension: [OR 2.98 95% CI 2.37-3.75 and OR 2.88 (2.22-3.74)]. Cardiovascular disease was strongly associated with both severity and mortality, respectively [OR 4.02 (2.76-5.86) and OR 6.34 (3.71-10.84)]. On the contrary, the use of ACEI/ARB, was not associate with severity of COVID-19.
CONCLUSION
CONCLUSIONS
In conclusion, diabetes, hypertension and especially cardiovascular disease, are important risk factors for severity and mortality in COVID-19 infected people and are targets that must be intensively addressed in the management of this infection.
Identifiants
pubmed: 32874207
doi: 10.1186/s13098-020-00586-4
pii: 586
pmc: PMC7456786
doi:
Types de publication
Journal Article
Langues
eng
Pagination
75Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Z Gesundh Wiss. 2020 Apr 21;:1-4
pubmed: 32318325
Curr Cardiol Rep. 2020 Apr 14;22(5):31
pubmed: 32291526
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):567-571
pubmed: 32141280
J Clin Virol. 2020 Jun;127:104364
pubmed: 32311650
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Diabetes Care. 2020 Jul;43(7):1392-1398
pubmed: 32409502
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899
JAMA. 2020 Feb 24;:
pubmed: 32091533
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Metabolism. 2020 Jun;107:154243
pubmed: 32320740
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
JAMA Cardiol. 2020 Mar 27;:
pubmed: 32219356
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Can J Cardiol. 2018 May;34(5):575-584
pubmed: 29459239
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Metabolism. 2020 Jul;108:154244
pubmed: 32320741
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
JAMA. 2020 Apr 6;:
pubmed: 32250385
JAMA Intern Med. 2020 Mar 13;:
pubmed: 32167524
Research (Wash D C). 2020 Apr 19;2020:2402961
pubmed: 32377638
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Hypertension. 2020 Aug;76(2):366-372
pubmed: 32564693
Int J Cardiol. 2020 Jul 15;311:116-121
pubmed: 32291207
JAMA Cardiol. 2020 Apr 23;:
pubmed: 32324209
PLoS One. 2020 Mar 19;15(3):e0230548
pubmed: 32191764
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Med Virol. 2020 Jun;92(6):564-567
pubmed: 32115733
Chin Med J (Engl). 2020 May 5;133(9):1032-1038
pubmed: 32118640
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
JAMA. 2020 Feb 7;:
pubmed: 32031570
JAMA. 2020 Apr 22;:
pubmed: 32320003
Hypertens Res. 2020 Jul;43(7):648-654
pubmed: 32341442
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Rev Med Virol. 2018 May;28(3):e1977
pubmed: 29664167
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899
pubmed: 32408793
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Arch Endocrinol Metab. 2020 May-Jun;64(3):199-200
pubmed: 32555985
Radiology. 2020 Aug;296(2):E86-E96
pubmed: 32301647
Thorax. 2003 Aug;58(8):686-9
pubmed: 12885985
Pharmacol Res. 2020 Aug;158:104927
pubmed: 32422341
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545
pubmed: 32408118
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267
pubmed: 32209890
JAMA Neurol. 2020 Apr 10;:
pubmed: 32275288
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
Hypertension. 2020 Jul;76(1):51-58
pubmed: 32348166